Meizhong Jin

This inventor holds 25 USPTO granted patents and 18 published patent applications, plus 3 CIPO patents and 10 EPO patents, primarily in Antiviral Agents. Top assignees: Enanta Pharmaceuticals, Inc., Osi Pharmaceuticals, Inc., Arvinas Operations, Inc.. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Meizhong Jin. Retrieved from https://idiyas.com/inventor/meizhong-jin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 18)

% Patents Active = 84.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 9.1

ph-index = 9

Forward Citations = 202(Granted Patents)

Location History:

Farmingdale, NY (US) (2010)
Dix Hills, NY (US) (2011 - 2013)
East Northport, NY (US) (2014 - 2022)
Wellesley, MA (US) (2019 - 2024)

Company Filing History:

12 out of 299

Enanta Pharmaceuticals, Inc.

patents

9 out of 118

Osi Pharmaceuticals, Inc.

patents

4 out of 67

Arvinas Operations, Inc.

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Hepatitis B

Antiviral Agents

Protein Degradation

Cancer Treatment

mTOR Inhibitors

Bicyclic Compounds

Pteridinones

Imidazopyr

Imidazotriazines

Kinase Inhibitors

Motor Inhibitors

Furo[3,2-C]pyridines

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12264157 - Compounds and methods for the enhanced degradation of targeted proteins (2025-04-01),

2. 12054493 - Hepatitis B antiviral agents (2024-08-06),

3. 11512083 - Compounds and methods for the enhanced degradation of targeted proteins (2022-11-29),

4. 11352351 - Compounds and methods for the targeted degradation of androgen receptor (2022-06-07),

5. 10934306 - Hepatitis B antiviral agents (2021-03-02),

6. 10738035 - Hepatitis B antiviral agents (2020-08-11),

7. 10730870 - Compounds and methods for the enhanced degradation of targeted proteins (2020-08-04),

8. 10702528 - Hepatitis B antiviral agents (2020-07-07),

9. 10640511 - Hepatitis B antiviral agents (2020-05-05),

10. 10538532 - Hepatitis B antiviral agents (2020-01-21),

11. 10442788 - Hepatitis B antiviral agents (2019-10-15),

12. 10301255 - Hepatitis B antiviral agents (2019-05-28),

13. 10280175 - Hepatitis B antiviral agents (2019-05-07),

14. 10189846 - Hepatitis B antiviral agents (2019-01-29),

15. 10179792 - Hepatitis B antiviral agents (2019-01-15),

Title: Biography of Meizhong Jin

Introduction: Meizhong Jin is a prominent inventor based in Dix Hills, NY (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that enhance the degradation of targeted proteins. With a total of 13 patents to his name, Jin's work has the potential to impact various therapeutic areas.

Latest Patents: One of his latest patents focuses on bifunctional compounds that serve as modulators of targeted ubiquitination. These compounds are designed to inhibit a variety of polypeptides and proteins that are degraded by the compounds. The invention involves a VHL ligand that binds to the ubiquitin ligase and a moiety that binds to a target protein, facilitating its degradation. This innovative approach exhibits a broad range of pharmacological activities, showcasing the potential of these compounds in therapeutic applications.

Career Highlights: Throughout his career, Meizhong Jin has worked with notable companies in the pharmaceutical industry. He has been associated with Osi Pharmaceuticals, Inc. and Arvinas Operations, Inc., where he has contributed to groundbreaking research and development efforts.

Collaborations: Jin has collaborated with esteemed colleagues, including Jing Wang and Andrew Philip Crew. These partnerships have further enriched his research and have led to advancements in the field of protein degradation.

Conclusion: Meizhong Jin's innovative work in the development of

Profile summary based on public USPTO records.